Masazumi Kamohara

This inventor holds 11 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignees: Astellas Pharma Gmbh, Yamanouchi Pharmaceutical Company Ltd., Helix Research Institute. Active years: 2003-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Masazumi Kamohara. Retrieved from https://idiyas.com/inventor/masazumi-kamohara

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 2)

% Patents Active = 72.7

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 5.8

ph-index = 2

Forward Citations = 10(Granted Patents)

Location History:

Tsukuba, JP (2005 - 2007)
Ibaraki, JP (2003 - 2010)
Tokyo, JP (2015 - 2018)

Company Filing History:

Yamanouchi Pharmaceutical Company Ltd.

patents

2 out of 3

Helix Research Institute

patents

where one patent can have more than one assignee

Years Active: 2003-2018

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9902782 - Anti-human tie-2 antibody (2018-02-27),

2. 9683051 - Anti-human tie-2 antibody (2017-06-20),

3. 9127055 - Method of treating pain with anti-human NGF antibody (2015-09-08),

4. 8986952 - Anti-human NGF antibody (2015-03-24),

5. 7662775 - Method for screening agents for the treatment of diabetes (2010-02-16),

6. 7405051 - Method of screening antiplatelet agents (2008-07-29),

7. 7341849 - Polynucleotides encoding SREB1 receptor (2008-03-11),

8. 7217800 - Peptide leukotriene receptor (2007-05-15),

9. 6878525 - Peptide leukotriene receptor (2005-04-12),

10. 6808899 - Polynucleotides encoding SREB3 receptor (2004-10-26),

11. 6555344 - Polynucleotides encoding SRE B2 receptor (2003-04-29),

Title: Masazumi Kamohara: Innovator in Anti-Human Tie2 Antibody Research

Introduction

Masazumi Kamohara is a prominent inventor based in Ibaraki, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for medical applications. With a total of 11 patents to his name, Kamohara's work focuses on innovative solutions for treating serious health conditions.

Latest Patents

One of Kamohara's latest patents is an anti-human Tie2 antibody designed to prevent or treat diabetic macular edema, diabetic retinopathy, and critical limb ischemia. This antibody works by binding to human Tie2, thereby activating it. The invention includes a detailed composition of the antibody, which comprises four heavy chain variable regions and four light chain variable regions. The heavy chain variable region consists of the amino acid sequence of the amino acid numbers 1 to 122 of SEQ ID NO: 2, while the light chain variable region consists of the amino acid sequence of the amino acid numbers 1 to 113 of SEQ ID NO: 4. Each heavy chain variable region and light chain variable region together form one antigen-binding site, resulting in an antibody with four antigen-binding sites.

Career Highlights

Throughout his career, Kamohara has worked with notable companies in the pharmaceutical industry. He has been associated with Astellas Pharma GmbH and Yamanouchi Pharmaceutical Company Ltd., where he has contributed to various research and development projects. His expertise in antibody research has positioned him as a key figure in the field.

Collaborations

Kamohara has collaborated with several professionals in his field, including Jun Takasaki and Mitsuyuki Matsumoto. These collaborations have further enhanced his research and development efforts, leading to innovative solutions in biotechnology.

Conclusion

Masazumi Kamohara's work in developing anti-human Tie2 antibodies showcases his commitment to advancing medical science. His contributions have the potential to significantly impact the treatment of serious health conditions, making him a noteworthy inventor in the field of biotechnology.

Profile summary based on public USPTO records.